SPIRITT (STUDY 20060141): A RANDOMISED PHASE 2 STUDY OF FOLFIRI WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 2ND-LINE TREATMENT (tx) IN PATIENTS (pts) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)

被引：0
|
作者：
Hecht, J. R. [1 ]
Cohn, A. [2 ]
Dakhil, S. [3 ]
Saleh, M.
Cline-Burkhardt, M. [4 ]
Piperdi, B. [5 ]
Tian, Y. [6 ]
Go, W. [6 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Kansas, Liberal, KS USA
[4] US Oncol, Austin, TX USA
[5] Montefiore Med Ctr, New York, NY USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second -line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
    Hecht, J. Randolph
    Cohn, Allen Lee
    Dakhil, Shaker R.
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Cohn, Allen Lee
    Hecht, J. Randolph
    Dakhil, Shaker
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] PEAK (STUDY 20070509): A RANDOMISED PHASE 2 STUDY OF mFOLFOX6 WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 1ST-LINE TREATMENT (tx) IN PATIENTS (pts) WITH UNRESECTABLE WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)
    Schwartzberg, L.
    Rivera, F.
    Karthaus, M.
    Fasola, G.
    Canon, J. -L.
    Yu, H.
    Go, W.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 62 - 62
  • [4] PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Steven Schwartzberg, Lee
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Yu, Hua
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [6] Pooled safety results from SPIRITT: A multicenter, open-label, randomized, phase II study of FOLFIRI with panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Hecht, J. R.
    Dakhil, S. R.
    Saleh, M. N.
    Piperdi, B.
    Cline-Burkhardt, M.
    Kocs, D. M.
    DeMarco, L. C.
    Chen, L.
    Krishnan, K.
    Cohn, A. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC)
    Schwartzberg, Lee Steven
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Yu, Hua
    Oliner, Kelly S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Cohn, Allen
    Dakhil, Shaker
    Saleh, Mansoor
    Piperdi, Bilal
    Cline-Burkhardt, Mika
    Tian, Ying
    Go, William Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (02) : 72 - 80
  • [9] Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.
    Peeters, Marc
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Attili Venkatasatya
    Thomas, Anne
    Tjulandin, Sergei
    Guan, Xuesong
    Hoang, Tien
    Hei, Yong Jiang
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345